M
Marc A. Pfeffer
Researcher at Brigham and Women's Hospital
Publications - 815
Citations - 143710
Marc A. Pfeffer is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Heart failure & Myocardial infarction. The author has an hindex of 166, co-authored 765 publications receiving 133043 citations. Previous affiliations of Marc A. Pfeffer include Partners HealthCare & University of Miami.
Papers
More filters
Journal ArticleDOI
Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT).
Faisal Shamshad,Satish Kenchaiah,Peter V. Finn,Jordi Soler-Soler,John J.V. McMurray,Eric J. Velazquez,Aldo P. Maggioni,Robert M. Califf,Karl Swedberg,Lars Køber,Yuri N. Belenkov,Sergei Varshavsky,Marc A. Pfeffer,Scott D. Solomon +13 more
TL;DR: ValIANT was a double-blind, randomized, controlled trial comparing valsartan, captopril, and their combination in high-risk patients post-MI, suggesting an estimated incidence of approximately 1% within the first 30 days of follow-up.
Journal ArticleDOI
Renal outcomes with aliskiren in patients with type 2 diabetes: A prespecified secondary analysis of the ALTITUDE randomised controlled trial
Hiddo J.L. Heerspink,Frederik Persson,Barry M. Brenner,Nish Chaturvedi,Patrick Brunel,John J.V. McMurray,Akshay S. Desai,Scott D. Solomon,Marc A. Pfeffer,Hans-Henrik Parving,de Dick Zeeuw +10 more
TL;DR: Aliskiren showed no beneficial effect on hard renal outcomes in the overall population or in various subgroups, but delayed progression to micro albuminuria and macroalbuminuria, and improved regression to microalbum inuria and normo Albuminuria classes.
Journal ArticleDOI
Systemic hemodynamic effects of endothelin in rats.
TL;DR: The intriguing possibility that endothelin may play a role in both the control of normal vascular smooth muscle tone and in the pathogenesis of vasospastic disorders is raised.
Journal ArticleDOI
Impact of erythropoiesis-stimulating agents on morbidity and mortality in patients with heart failure: an updated, post-TREAT meta-analysis
TL;DR: The effect of treating anaemia with an ESA in patients with heart failure is examined in a meta‐analysis of randomized clinical trials, including the recently reported TREAT study.
Journal ArticleDOI
Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints
Patrick Rossignol,Rajiv Agarwal,Rajiv Agarwal,Bernard Canaud,Alan Charney,Gilles Chatellier,Jonathan C. Craig,Jonathan C. Craig,William C. Cushman,Ron T. Gansevoort,Bengt Fellström,Dahlia Garza,Nicolas Guzman,Frank A. Holtkamp,Gérard M. London,Ziad A. Massy,Alexandre Mebazaa,Peter G. M. Mol,Marc A. Pfeffer,Yves Rosenberg,Luis M. Ruilope,Jonathan H. Seltzer,Amil M. Shah,Salim Shah,Bhupinder Singh,Bergur V. Stefánsson,Norman Stockbridge,Wendy Gattis Stough,Kristian Thygesen,Michael Walsh,Christoph Wanner,David G. Warnock,Christopher S. Wilcox,Janet Wittes,Bertram Pitt,Aliza Thompson,Faiez Zannad +36 more
TL;DR: Cardiovascular and renal clinical trialists must partner to address the uncertainties in the field through collaborative research and design clinical trials that reflect the specific needs of the chronic and end-stage kidney disease populations, with the shared goal of generating robust evidence to guide the management of cardiovascular disease in patients with kidney disease.